Archimedes Jao
General Practice · Brooklyn, NYNPI 1932438470
Payments from drug & device makers
Across 185 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$1K
- Viiv Healthcare Company$989
- AbbVie$576
- Johnson & Johnson$349
- Teva Pharmaceuticals USA, Inc.$46
- Indivior Inc.$40
- plus $143 from 6 others
What the payments were for
- Food & beverage$3,23498%
- Education$622%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 66 | $1,153 |
| Viiv Healthcare Company | 56 | $989 |
| AbbVie | 24 | $576 |
| Johnson & Johnson | 29 | $349 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
| Indivior Inc. | 2 | $40 |
| Exact Sciences | 1 | $34 |
| Lilly USA, LLC | 1 | $27 |
| Pfizer | 1 | $22 |
| Merck | 1 | $21 |
| Napo Pharmaceuticals Inc | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
How this compares
$3,296 in reported general payments places this provider in the 95th percentile of 5,764 general practice providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 126 | $462,868 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 45 | $171,619 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 31 | $109,768 |
| DovatoDolutegravir Sodium/Lamivudine | 22 | $60,413 |
| JulucaDolutegravir/Rilpivirine | 13 | $43,064 |
| TrulicityDulaglutide | 26 | $24,962 |
| FarxigaDapagliflozin Propanediol | 29 | $16,363 |
| EliquisApixaban | 26 | $15,047 |
| JanuviaSitagliptin Phosphate | 22 | $12,042 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $8,649 |
| EntrestoSacubitril/Valsartan | 11 | $8,524 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,910 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 11 | $4,889 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $4,312 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $1,153 | $634,486171 claims |
| Viiv Healthcare CompanyTriumeq, Dovato, Juluca | $989 | $213,24566 claims |
| Lilly USA, LLCTrulicity | $27 | $24,96226 claims |
| MerckJanuvia, Janumet | $21 | $20,69137 claims |
| PfizerEliquis | $22 | $15,04726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,764 general practice providers in New York.
Other general practice in Brooklyn
- Stuart DitchekBrooklyn$171K
- Anthony RamirezBrooklyn$114K
- Isaac TawilBrooklyn$60K
- Jerome CantorBrooklyn$32K
- Margarita DegtyarevaBrooklyn$14K
- Mark HochmanHicksville$5.1M
- Sarah AtkinsonRochester$4.2M
- Michael MashaalRoslyn$1.9M
- David RiceEast Amherst$1.2M
- Alejandra Gonzalez-DuarteNew York$519K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.